Significance of Programmed Cell Death Pathways in Neurodegenerative Diseases

Programmed cell death (PCD) is a form of cell death distinct from accidental cell death (ACD) and is also referred to as regulated cell death (RCD). Typically, PCD signaling events are precisely regulated by various biomolecules in both spatial and temporal contexts to promote neuronal development,...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-09, Vol.25 (18), p.9947
Main Authors: Guo, Dong, Liu, Zhihao, Zhou, Jinglin, Ke, Chongrong, Li, Daliang
Format: Article
Language:English
Subjects:
Amyotrophic lateral sclerosis
Animals
Apoptosis
Autophagy
Cell death
Cytochrome
Degeneration
Disease
Ferroptosis
Health aspects
Homeostasis
Humans
Kinases
Ligands
Mitochondria
Nervous system
neurodegenerative diseases (NDDs)
Neurodegenerative Diseases - metabolism
Neurodegenerative Diseases - pathology
Neurons - metabolism
Neurons - pathology
Permeability
Physiology
programmed cell death
Proteins
Review
Signal Transduction
Stem cells
Traumatic brain injury
Tumor necrosis factor-TNF
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Programmed cell death (PCD) is a form of cell death distinct from accidental cell death (ACD) and is also referred to as regulated cell death (RCD). Typically, PCD signaling events are precisely regulated by various biomolecules in both spatial and temporal contexts to promote neuronal development, establish neural architecture, and shape the central nervous system (CNS), although the role of PCD extends beyond the CNS. Abnormalities in PCD signaling cascades contribute to the irreversible loss of neuronal cells and function, leading to the onset and progression of neurodegenerative diseases. In this review, we summarize the molecular processes and features of different modalities of PCD, including apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis, and other novel forms of PCD, and their effects on the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), multiple sclerosis (MS), traumatic brain injury (TBI), and stroke. Additionally, we examine the key factors involved in these PCD signaling pathways and discuss the potential for their development as therapeutic targets and strategies. Therefore, therapeutic strategies targeting the inhibition or facilitation of PCD signaling pathways offer a promising approach for clinical applications in treating neurodegenerative diseases.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25189947